Structure Therapeutics (GPCR) Enterprise Value (2022 - 2026)

Structure Therapeutics' Enterprise Value history runs 5 years deep, the most recent figure standing at -$2.6 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 72.39% year-over-year to -$2.6 billion; the TTM figure through Mar 2026 stood at -$2.6 billion (down 72.39% YoY), while the FY2025 annual figure was -$1.4 billion, up 9.01% from the prior year.
• Enterprise Value was -$2.6 billion for Q1 2026 at Structure Therapeutics, down from -$1.4 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$90.8 million in Q4 2022 to a low of -$2.6 billion in Q1 2026.
• Historically, Enterprise Value has averaged -$1.0 billion across 5 years, with a median of -$1.1 billion in 2025.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value slumped 702.35% in 2024, then soared 46.59% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$90.8 million in 2022, then sank by 414.44% to -$467.3 million in 2023, then tumbled by 240.1% to -$1.6 billion in 2024, then rose by 9.01% to -$1.4 billion in 2025, then slumped by 79.84% to -$2.6 billion in 2026.
• The last three Enterprise Value figures came in at -$2.6 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.